Interestingly, in 15% of mucinous carcinomas, multiple KRAS mutations were detected, further supporting the key role of KRAS mutations in the pathway of neoplastic transformation involving mucinous adenoma-borderline tumor-carcinoma [113]. Here, KRAS is linked to mucinous cystadenoma.